 Michael Arnold
Concepts (512)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rhabdomyosarcoma | 7 | 2023 | 52 | 2.190 |
Why?
| | Sarcoma | 6 | 2024 | 137 | 1.540 |
Why?
| | Cancer Survivors | 13 | 2023 | 203 | 1.530 |
Why?
| | Wilms Tumor | 4 | 2022 | 66 | 1.510 |
Why?
| | Desmoplastic Small Round Cell Tumor | 3 | 2022 | 3 | 1.480 |
Why?
| | Sarcoma, Ewing | 4 | 2022 | 62 | 1.470 |
Why?
| | Kidney Neoplasms | 5 | 2022 | 325 | 1.300 |
Why?
| | Neoplasms, Second Primary | 8 | 2023 | 91 | 1.260 |
Why?
| | Biomarkers, Tumor | 7 | 2023 | 1045 | 1.240 |
Why?
| | Bone Neoplasms | 4 | 2024 | 194 | 1.180 |
Why?
| | Immunohistochemistry | 6 | 2016 | 1644 | 1.030 |
Why?
| | Oncogene Proteins, Fusion | 7 | 2022 | 178 | 0.990 |
Why?
| | Thyroid Neoplasms | 5 | 2021 | 262 | 0.970 |
Why?
| | Rhabdomyosarcoma, Alveolar | 3 | 2021 | 10 | 0.870 |
Why?
| | Hirschsprung Disease | 5 | 2023 | 87 | 0.810 |
Why?
| | Gene Fusion | 3 | 2020 | 18 | 0.800 |
Why?
| | Gastritis | 3 | 2024 | 84 | 0.790 |
Why?
| | Myogenic Regulatory Factors | 8 | 2009 | 49 | 0.750 |
Why?
| | Child | 44 | 2024 | 18537 | 0.720 |
Why?
| | Gallbladder Diseases | 1 | 2019 | 6 | 0.670 |
Why?
| | Inclusion Bodies | 1 | 2019 | 24 | 0.670 |
Why?
| | Pyridines | 3 | 2022 | 425 | 0.650 |
Why?
| | Azabicyclo Compounds | 1 | 2017 | 5 | 0.610 |
Why?
| | Niacin | 1 | 2017 | 19 | 0.600 |
Why?
| | Neoplasms, Radiation-Induced | 5 | 2021 | 65 | 0.590 |
Why?
| | Sarcoma, Synovial | 2 | 2018 | 10 | 0.590 |
Why?
| | Helicobacter | 1 | 2016 | 5 | 0.570 |
Why?
| | Helicobacter Infections | 1 | 2016 | 26 | 0.560 |
Why?
| | Stomach | 1 | 2016 | 101 | 0.550 |
Why?
| | Carbodiimides | 2 | 2006 | 4 | 0.540 |
Why?
| | Imines | 2 | 2006 | 7 | 0.540 |
Why?
| | Alkaloids | 2 | 2006 | 22 | 0.540 |
Why?
| | Child, Preschool | 23 | 2024 | 9164 | 0.540 |
Why?
| | Breast Neoplasms | 6 | 2023 | 1872 | 0.530 |
Why?
| | Rhabdomyosarcoma, Embryonal | 3 | 2022 | 16 | 0.530 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2017 | 91 | 0.530 |
Why?
| | Biopsy | 9 | 2019 | 1056 | 0.530 |
Why?
| | Infant | 19 | 2023 | 7992 | 0.530 |
Why?
| | Chromosomal Proteins, Non-Histone | 2 | 2013 | 101 | 0.510 |
Why?
| | Neoplasms | 8 | 2022 | 2114 | 0.500 |
Why?
| | Adolescent | 30 | 2024 | 17935 | 0.500 |
Why?
| | Frozen Sections | 1 | 2015 | 23 | 0.500 |
Why?
| | Colestipol | 1 | 2014 | 1 | 0.500 |
Why?
| | Anti-Bacterial Agents | 3 | 2022 | 1486 | 0.500 |
Why?
| | Ion Exchange Resins | 1 | 2014 | 5 | 0.500 |
Why?
| | Humans | 77 | 2024 | 115859 | 0.490 |
Why?
| | Allylamine | 1 | 2014 | 7 | 0.490 |
Why?
| | Thyroid Diseases | 1 | 2015 | 30 | 0.490 |
Why?
| | Pathology, Surgical | 1 | 2014 | 7 | 0.490 |
Why?
| | Intestines | 2 | 2015 | 325 | 0.490 |
Why?
| | Biopsy, Fine-Needle | 1 | 2015 | 64 | 0.490 |
Why?
| | Transcription Factors | 6 | 2017 | 1535 | 0.490 |
Why?
| | Thyroid Gland | 1 | 2015 | 83 | 0.480 |
Why?
| | Gastrointestinal Agents | 1 | 2014 | 60 | 0.470 |
Why?
| | Practice Guidelines as Topic | 4 | 2019 | 1405 | 0.470 |
Why?
| | S100 Proteins | 1 | 2014 | 39 | 0.470 |
Why?
| | Specimen Handling | 1 | 2014 | 157 | 0.450 |
Why?
| | Cerebral Ventricle Neoplasms | 1 | 2013 | 4 | 0.440 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2013 | 17 | 0.430 |
Why?
| | Anticholesteremic Agents | 1 | 2014 | 129 | 0.430 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2014 | 219 | 0.430 |
Why?
| | DNA-Binding Proteins | 4 | 2013 | 1318 | 0.420 |
Why?
| | Rectum | 4 | 2023 | 151 | 0.410 |
Why?
| | Female | 49 | 2024 | 60070 | 0.410 |
Why?
| | Young Adult | 20 | 2023 | 10508 | 0.400 |
Why?
| | DNA | 2 | 2017 | 1357 | 0.380 |
Why?
| | Skin Neoplasms | 2 | 2019 | 760 | 0.380 |
Why?
| | Societies, Medical | 1 | 2014 | 685 | 0.370 |
Why?
| | Guideline Adherence | 1 | 2014 | 497 | 0.360 |
Why?
| | Soft Tissue Neoplasms | 2 | 2024 | 90 | 0.360 |
Why?
| | Male | 40 | 2024 | 56103 | 0.360 |
Why?
| | Guanidines | 2 | 2006 | 33 | 0.350 |
Why?
| | WT1 Proteins | 2 | 2022 | 12 | 0.330 |
Why?
| | Predictive Value of Tests | 6 | 2017 | 1813 | 0.330 |
Why?
| | Paired Box Transcription Factors | 3 | 2020 | 37 | 0.320 |
Why?
| | Risk Assessment | 8 | 2021 | 2992 | 0.320 |
Why?
| | Adult | 27 | 2023 | 30814 | 0.320 |
Why?
| | Retrospective Studies | 15 | 2024 | 12615 | 0.310 |
Why?
| | Risk Factors | 14 | 2023 | 8715 | 0.300 |
Why?
| | Gram-Negative Bacteria | 2 | 2018 | 67 | 0.300 |
Why?
| | Diagnosis, Differential | 5 | 2020 | 1359 | 0.290 |
Why?
| | Bone Development | 1 | 2007 | 48 | 0.280 |
Why?
| | Pediatrics | 1 | 2014 | 985 | 0.280 |
Why?
| | Colon | 3 | 2019 | 234 | 0.280 |
Why?
| | Pyrimidines | 2 | 2006 | 376 | 0.280 |
Why?
| | Intestinal Mucosa | 4 | 2019 | 528 | 0.270 |
Why?
| | Bone and Bones | 2 | 2018 | 283 | 0.270 |
Why?
| | Antineoplastic Agents | 4 | 2022 | 1891 | 0.260 |
Why?
| | Vinyl Compounds | 1 | 2005 | 5 | 0.260 |
Why?
| | Guanidine | 1 | 2005 | 18 | 0.260 |
Why?
| | Cartilage | 1 | 2007 | 182 | 0.250 |
Why?
| | Survivors | 2 | 2019 | 404 | 0.250 |
Why?
| | Radiotherapy | 3 | 2021 | 177 | 0.250 |
Why?
| | Carcinoma, Renal Cell | 2 | 2020 | 167 | 0.240 |
Why?
| | Infant, Newborn | 10 | 2022 | 5084 | 0.240 |
Why?
| | Chondrocytes | 1 | 2007 | 199 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 4 | 2020 | 2201 | 0.240 |
Why?
| | Eosinophilia | 2 | 2024 | 187 | 0.240 |
Why?
| | Mutation | 5 | 2021 | 3371 | 0.240 |
Why?
| | Pathology | 1 | 2024 | 21 | 0.230 |
Why?
| | Duodenitis | 1 | 2024 | 7 | 0.230 |
Why?
| | Polyketides | 1 | 2023 | 3 | 0.230 |
Why?
| | Education, Distance | 1 | 2024 | 36 | 0.230 |
Why?
| | Dysautonomia, Familial | 1 | 2023 | 2 | 0.220 |
Why?
| | Disease-Free Survival | 4 | 2020 | 621 | 0.220 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1360 | 0.220 |
Why?
| | Microbial Sensitivity Tests | 3 | 2022 | 299 | 0.220 |
Why?
| | Orbital Neoplasms | 1 | 2023 | 21 | 0.220 |
Why?
| | SMARCB1 Protein | 2 | 2013 | 17 | 0.220 |
Why?
| | Prognosis | 7 | 2023 | 3344 | 0.220 |
Why?
| | Eyelids | 1 | 2023 | 29 | 0.220 |
Why?
| | Retinal Degeneration | 1 | 2023 | 30 | 0.210 |
Why?
| | Mice | 17 | 2023 | 15085 | 0.210 |
Why?
| | Enterocolitis | 1 | 2023 | 33 | 0.210 |
Why?
| | Telomere Homeostasis | 2 | 2020 | 24 | 0.200 |
Why?
| | Ribonucleotide Reductases | 1 | 2022 | 21 | 0.200 |
Why?
| | Bone Marrow | 1 | 2023 | 248 | 0.200 |
Why?
| | Norwood Procedures | 1 | 2022 | 23 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2019 | 703 | 0.200 |
Why?
| | Age Factors | 4 | 2019 | 2911 | 0.200 |
Why?
| | Vulvar Neoplasms | 1 | 2021 | 10 | 0.200 |
Why?
| | Radiation Dosage | 2 | 2019 | 142 | 0.200 |
Why?
| | Muscle Proteins | 3 | 2017 | 214 | 0.200 |
Why?
| | Telomere Shortening | 1 | 2021 | 18 | 0.200 |
Why?
| | MEF2 Transcription Factors | 8 | 2009 | 54 | 0.200 |
Why?
| | Incidence | 7 | 2022 | 2336 | 0.200 |
Why?
| | Appendix | 1 | 2021 | 26 | 0.190 |
Why?
| | Radiation | 1 | 2021 | 24 | 0.190 |
Why?
| | Alphapapillomavirus | 1 | 2021 | 36 | 0.190 |
Why?
| | Neurodegenerative Diseases | 1 | 2023 | 93 | 0.190 |
Why?
| | MyoD Protein | 2 | 2021 | 27 | 0.190 |
Why?
| | Histone Deacetylases | 3 | 2007 | 196 | 0.190 |
Why?
| | Gonorrhea | 1 | 2022 | 54 | 0.190 |
Why?
| | Biliary Tract Neoplasms | 1 | 2021 | 20 | 0.190 |
Why?
| | Middle Aged | 15 | 2021 | 27078 | 0.190 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2022 | 113 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 3 | 2023 | 816 | 0.190 |
Why?
| | Drug Resistance, Bacterial | 1 | 2022 | 156 | 0.190 |
Why?
| | Forkhead Box Protein O1 | 1 | 2020 | 14 | 0.190 |
Why?
| | Schwann Cells | 1 | 2020 | 27 | 0.190 |
Why?
| | Colonic Neoplasms | 2 | 2013 | 222 | 0.190 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2023 | 862 | 0.180 |
Why?
| | Colitis | 2 | 2021 | 226 | 0.180 |
Why?
| | Chromosome Breakpoints | 1 | 2020 | 6 | 0.180 |
Why?
| | Rhabdomyoma | 1 | 2020 | 10 | 0.180 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2018 | 165 | 0.180 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2020 | 25 | 0.180 |
Why?
| | Nanoparticles | 2 | 2015 | 316 | 0.180 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 394 | 0.180 |
Why?
| | Colitis, Ischemic | 1 | 2019 | 6 | 0.180 |
Why?
| | Diagnostic Errors | 3 | 2017 | 151 | 0.180 |
Why?
| | Reproducibility of Results | 3 | 2021 | 2807 | 0.170 |
Why?
| | Phenotype | 5 | 2015 | 2859 | 0.170 |
Why?
| | Ventricular Outflow Obstruction | 1 | 2020 | 37 | 0.170 |
Why?
| | Structure-Activity Relationship | 2 | 2018 | 511 | 0.170 |
Why?
| | Heart Neoplasms | 1 | 2020 | 50 | 0.170 |
Why?
| | Neurogenesis | 1 | 2020 | 102 | 0.170 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2021 | 2004 | 0.170 |
Why?
| | Appendiceal Neoplasms | 1 | 2019 | 14 | 0.170 |
Why?
| | Colitis, Ulcerative | 1 | 2021 | 106 | 0.170 |
Why?
| | Neural Stem Cells | 1 | 2020 | 114 | 0.170 |
Why?
| | Carcinoid Tumor | 1 | 2019 | 25 | 0.170 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2020 | 448 | 0.170 |
Why?
| | Gallbladder | 1 | 2019 | 14 | 0.170 |
Why?
| | Neurofibromatosis 1 | 1 | 2019 | 36 | 0.170 |
Why?
| | Research Report | 1 | 2019 | 76 | 0.170 |
Why?
| | Vagina | 1 | 2021 | 148 | 0.170 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2020 | 60 | 0.170 |
Why?
| | Prospective Studies | 5 | 2021 | 6276 | 0.160 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2019 | 19 | 0.160 |
Why?
| | Cholecystectomy | 1 | 2019 | 45 | 0.160 |
Why?
| | Enteric Nervous System | 1 | 2019 | 26 | 0.160 |
Why?
| | Telomere-Binding Proteins | 1 | 2020 | 88 | 0.160 |
Why?
| | Gene Rearrangement | 2 | 2022 | 136 | 0.160 |
Why?
| | Glucose Transporter Type 1 | 1 | 2018 | 41 | 0.160 |
Why?
| | Radiation Injuries | 1 | 2019 | 128 | 0.160 |
Why?
| | Anal Canal | 1 | 2019 | 83 | 0.160 |
Why?
| | Ohio | 2 | 2017 | 136 | 0.160 |
Why?
| | Digestive System Surgical Procedures | 1 | 2019 | 89 | 0.160 |
Why?
| | Topoisomerase II Inhibitors | 1 | 2018 | 23 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2021 | 1143 | 0.160 |
Why?
| | Age of Onset | 1 | 2019 | 455 | 0.150 |
Why?
| | DNA Topoisomerases, Type II | 1 | 2018 | 45 | 0.150 |
Why?
| | Glioma | 1 | 2021 | 296 | 0.150 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 390 | 0.150 |
Why?
| | Epithelium | 1 | 2019 | 297 | 0.150 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2018 | 62 | 0.150 |
Why?
| | Carcinoma, Basal Cell | 1 | 2019 | 68 | 0.150 |
Why?
| | Escherichia coli | 2 | 2022 | 730 | 0.150 |
Why?
| | Curriculum | 1 | 2024 | 856 | 0.150 |
Why?
| | Eosinophilic Esophagitis | 1 | 2022 | 295 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 153 | 0.150 |
Why?
| | Half-Life | 1 | 2017 | 145 | 0.150 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2017 | 37 | 0.150 |
Why?
| | Animals | 17 | 2023 | 32158 | 0.150 |
Why?
| | Interleukin-8 | 1 | 2018 | 241 | 0.150 |
Why?
| | Povidone | 1 | 2017 | 5 | 0.150 |
Why?
| | Nephroma, Mesoblastic | 1 | 2017 | 3 | 0.150 |
Why?
| | Immunocompromised Host | 1 | 2019 | 197 | 0.150 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 187 | 0.140 |
Why?
| | Drug Discovery | 1 | 2018 | 124 | 0.140 |
Why?
| | Nuclear Receptor Coactivator 1 | 1 | 2017 | 10 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 2017 | 33 | 0.140 |
Why?
| | Oncogene Protein p21(ras) | 1 | 2017 | 16 | 0.140 |
Why?
| | Excipients | 1 | 2017 | 49 | 0.140 |
Why?
| | Pathology, Clinical | 1 | 2017 | 32 | 0.140 |
Why?
| | Cohort Studies | 6 | 2023 | 4960 | 0.140 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2021 | 289 | 0.140 |
Why?
| | Candidiasis | 1 | 2017 | 58 | 0.140 |
Why?
| | Cellulose | 1 | 2017 | 61 | 0.140 |
Why?
| | Esophagitis | 1 | 2017 | 65 | 0.140 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 5 | 0.130 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 8 | 0.130 |
Why?
| | Enterocolitis, Neutropenic | 1 | 2015 | 5 | 0.130 |
Why?
| | Heart Transplantation | 1 | 2022 | 671 | 0.130 |
Why?
| | Liver Neoplasms | 1 | 2020 | 521 | 0.130 |
Why?
| | Stereoisomerism | 2 | 2006 | 91 | 0.130 |
Why?
| | Survival Rate | 4 | 2023 | 1649 | 0.130 |
Why?
| | beta 2-Microglobulin | 1 | 2015 | 45 | 0.130 |
Why?
| | Virus Internalization | 1 | 2015 | 41 | 0.130 |
Why?
| | Cardiac Surgical Procedures | 1 | 2020 | 414 | 0.130 |
Why?
| | Receptors, Virus | 1 | 2015 | 76 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 944 | 0.130 |
Why?
| | Immunotherapy | 2 | 2018 | 481 | 0.130 |
Why?
| | Sarcoma, Experimental | 1 | 2015 | 5 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 935 | 0.130 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2019 | 666 | 0.130 |
Why?
| | Granuloma, Plasma Cell | 1 | 2015 | 11 | 0.120 |
Why?
| | Granuloma, Foreign-Body | 1 | 2015 | 10 | 0.120 |
Why?
| | Colesevelam Hydrochloride | 1 | 2014 | 7 | 0.120 |
Why?
| | Cholestyramine Resin | 1 | 2014 | 7 | 0.120 |
Why?
| | Information Dissemination | 1 | 2017 | 192 | 0.120 |
Why?
| | Thyroidectomy | 1 | 2015 | 52 | 0.120 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 169 | 0.120 |
Why?
| | Herpesvirus 1, Human | 1 | 2015 | 81 | 0.120 |
Why?
| | Neuroblastoma | 1 | 2015 | 130 | 0.120 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2016 | 310 | 0.120 |
Why?
| | Desmin | 1 | 2014 | 30 | 0.120 |
Why?
| | Albumins | 1 | 2015 | 91 | 0.120 |
Why?
| | Interleukin-6 | 1 | 2018 | 677 | 0.120 |
Why?
| | Social Media | 1 | 2017 | 135 | 0.120 |
Why?
| | Quality Control | 1 | 2014 | 150 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2015 | 173 | 0.120 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2015 | 59 | 0.120 |
Why?
| | Muscle, Skeletal | 4 | 2007 | 1459 | 0.120 |
Why?
| | Cerebral Ventricles | 1 | 2014 | 47 | 0.120 |
Why?
| | Tubulin | 1 | 2015 | 123 | 0.120 |
Why?
| | Paclitaxel | 1 | 2015 | 192 | 0.120 |
Why?
| | Keratins | 1 | 2014 | 176 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 548 | 0.110 |
Why?
| | MicroRNAs | 1 | 2020 | 610 | 0.110 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2014 | 60 | 0.110 |
Why?
| | Treatment Outcome | 5 | 2022 | 9163 | 0.110 |
Why?
| | Microscopy | 1 | 2014 | 124 | 0.110 |
Why?
| | Vascular Malformations | 1 | 2014 | 47 | 0.110 |
Why?
| | Ganglioneuroma | 1 | 2013 | 2 | 0.110 |
Why?
| | Cerebral Hemorrhage | 1 | 2014 | 96 | 0.110 |
Why?
| | Ileal Neoplasms | 1 | 2013 | 4 | 0.110 |
Why?
| | Glucose-6-Phosphatase | 1 | 2013 | 31 | 0.110 |
Why?
| | Hypertrophy | 2 | 2018 | 112 | 0.110 |
Why?
| | Food | 1 | 2015 | 160 | 0.110 |
Why?
| | Repressor Proteins | 2 | 2006 | 369 | 0.110 |
Why?
| | Follow-Up Studies | 5 | 2019 | 4443 | 0.110 |
Why?
| | Lateral Ventricles | 1 | 2013 | 22 | 0.110 |
Why?
| | Calcium Phosphates | 1 | 2013 | 25 | 0.110 |
Why?
| | Human Growth Hormone | 1 | 2013 | 38 | 0.110 |
Why?
| | Cell Line, Tumor | 5 | 2019 | 2749 | 0.110 |
Why?
| | United States | 7 | 2019 | 12319 | 0.110 |
Why?
| | Gastrointestinal Diseases | 1 | 2015 | 184 | 0.110 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2013 | 138 | 0.110 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2013 | 52 | 0.110 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2013 | 45 | 0.110 |
Why?
| | Neutropenia | 1 | 2013 | 127 | 0.100 |
Why?
| | COS Cells | 3 | 2007 | 175 | 0.100 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1088 | 0.100 |
Why?
| | Sepsis | 1 | 2018 | 521 | 0.100 |
Why?
| | Enteritis | 2 | 2024 | 82 | 0.100 |
Why?
| | Endocytosis | 1 | 2013 | 152 | 0.100 |
Why?
| | Patient Selection | 1 | 2015 | 655 | 0.100 |
Why?
| | Colonic Polyps | 1 | 2013 | 67 | 0.100 |
Why?
| | Rhabdoid Tumor | 1 | 2012 | 80 | 0.100 |
Why?
| | Brain Neoplasms | 1 | 2019 | 979 | 0.100 |
Why?
| | Feasibility Studies | 1 | 2014 | 750 | 0.100 |
Why?
| | Neurosurgical Procedures | 1 | 2013 | 157 | 0.100 |
Why?
| | Spinal Cord | 1 | 2014 | 351 | 0.100 |
Why?
| | Adenoma | 1 | 2013 | 187 | 0.090 |
Why?
| | Recurrence | 3 | 2024 | 950 | 0.090 |
Why?
| | Colonoscopy | 1 | 2013 | 204 | 0.090 |
Why?
| | Constipation | 2 | 2023 | 75 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2013 | 545 | 0.090 |
Why?
| | Sarcomeres | 2 | 2007 | 89 | 0.090 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1127 | 0.090 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.090 |
Why?
| | SEER Program | 2 | 2021 | 195 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2021 | 2416 | 0.090 |
Why?
| | Aged | 6 | 2019 | 19292 | 0.080 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2007 | 174 | 0.080 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2009 | 63 | 0.080 |
Why?
| | Coccidioidomycosis | 1 | 2008 | 7 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1725 | 0.080 |
Why?
| | Cell Proliferation | 3 | 2018 | 2196 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 47 | 0.080 |
Why?
| | Polyethylene Glycols | 1 | 2013 | 576 | 0.080 |
Why?
| | Risk | 2 | 2021 | 829 | 0.080 |
Why?
| | Doxorubicin | 2 | 2023 | 290 | 0.080 |
Why?
| | Waste Disposal, Fluid | 1 | 2008 | 45 | 0.070 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2007 | 796 | 0.070 |
Why?
| | Case-Control Studies | 3 | 2021 | 3054 | 0.070 |
Why?
| | Canada | 2 | 2019 | 337 | 0.070 |
Why?
| | Mice, Transgenic | 3 | 2007 | 1971 | 0.070 |
Why?
| | Dwarfism | 1 | 2007 | 15 | 0.070 |
Why?
| | Pressure | 1 | 2008 | 219 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 127 | 0.070 |
Why?
| | Gastroschisis | 1 | 2006 | 14 | 0.070 |
Why?
| | Colectomy | 2 | 2019 | 87 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2019 | 424 | 0.070 |
Why?
| | Actinin | 1 | 2006 | 13 | 0.070 |
Why?
| | Myopathies, Structural, Congenital | 1 | 2005 | 6 | 0.070 |
Why?
| | Cell Differentiation | 3 | 2008 | 1709 | 0.070 |
Why?
| | Neoplastic Stem Cells | 1 | 2009 | 330 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2018 | 2206 | 0.060 |
Why?
| | Neovascularization, Physiologic | 1 | 2007 | 174 | 0.060 |
Why?
| | Alkylation | 1 | 2005 | 19 | 0.060 |
Why?
| | Promoter Regions, Genetic | 2 | 2006 | 1130 | 0.060 |
Why?
| | Neoplasm Staging | 2 | 2020 | 1177 | 0.060 |
Why?
| | Aged, 80 and over | 4 | 2017 | 6434 | 0.060 |
Why?
| | Osteogenesis | 1 | 2007 | 184 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2007 | 2796 | 0.060 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 754 | 0.060 |
Why?
| | Base Sequence | 4 | 2013 | 2121 | 0.060 |
Why?
| | Molecular Medicine | 1 | 2024 | 2 | 0.060 |
Why?
| | Time Factors | 3 | 2019 | 6182 | 0.060 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2006 | 239 | 0.060 |
Why?
| | Daunorubicin | 1 | 2023 | 24 | 0.060 |
Why?
| | Podophyllotoxin | 1 | 2023 | 7 | 0.060 |
Why?
| | Anthracyclines | 1 | 2023 | 41 | 0.060 |
Why?
| | Public Opinion | 1 | 2024 | 59 | 0.060 |
Why?
| | Kinetin | 1 | 2023 | 1 | 0.060 |
Why?
| | Gait Ataxia | 1 | 2023 | 5 | 0.060 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 319 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2021 | 1758 | 0.050 |
Why?
| | Breast | 1 | 2023 | 139 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 211 | 0.050 |
Why?
| | Placenta | 1 | 2008 | 624 | 0.050 |
Why?
| | Deoxyadenine Nucleotides | 1 | 2022 | 13 | 0.050 |
Why?
| | Neisseria gonorrhoeae | 1 | 2022 | 20 | 0.050 |
Why?
| | Allosteric Regulation | 1 | 2022 | 84 | 0.050 |
Why?
| | Educational Measurement | 1 | 2024 | 265 | 0.050 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2024 | 202 | 0.050 |
Why?
| | Carrier Proteins | 1 | 2006 | 703 | 0.050 |
Why?
| | Mice, SCID | 2 | 2015 | 321 | 0.050 |
Why?
| | Gene Ontology | 1 | 2021 | 47 | 0.050 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2023 | 225 | 0.050 |
Why?
| | Haploinsufficiency | 1 | 2021 | 43 | 0.050 |
Why?
| | Colon, Sigmoid | 1 | 2021 | 15 | 0.050 |
Why?
| | Papillomaviridae | 1 | 2021 | 100 | 0.050 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2021 | 180 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2021 | 78 | 0.050 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2021 | 49 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 244 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2021 | 157 | 0.050 |
Why?
| | Administration, Oral | 1 | 2023 | 733 | 0.050 |
Why?
| | Myocardium | 1 | 2006 | 929 | 0.050 |
Why?
| | Cloaca | 1 | 2021 | 48 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2007 | 2365 | 0.040 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2021 | 182 | 0.040 |
Why?
| | Neoplasm, Residual | 1 | 2021 | 105 | 0.040 |
Why?
| | Transcription Initiation Site | 1 | 2020 | 40 | 0.040 |
Why?
| | Constriction, Pathologic | 1 | 2021 | 210 | 0.040 |
Why?
| | Genomic Instability | 1 | 2020 | 38 | 0.040 |
Why?
| | Mice, Knockout | 4 | 2007 | 2608 | 0.040 |
Why?
| | Genes, ras | 1 | 2020 | 91 | 0.040 |
Why?
| | Eosinophils | 1 | 2022 | 283 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2023 | 465 | 0.040 |
Why?
| | Students, Medical | 1 | 2024 | 280 | 0.040 |
Why?
| | Hepatocyte Growth Factor | 1 | 2019 | 33 | 0.040 |
Why?
| | Tissue Donors | 1 | 2022 | 331 | 0.040 |
Why?
| | Dose-Response Relationship, Radiation | 1 | 2019 | 130 | 0.040 |
Why?
| | Internet | 1 | 2024 | 601 | 0.040 |
Why?
| | Aneuploidy | 1 | 2020 | 86 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2019 | 246 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 261 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2019 | 67 | 0.040 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2019 | 57 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2022 | 1169 | 0.040 |
Why?
| | Introns | 1 | 2020 | 228 | 0.040 |
Why?
| | Anorectal Malformations | 1 | 2020 | 104 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 2 | 2013 | 312 | 0.040 |
Why?
| | Receptors, Interleukin-8A | 1 | 2018 | 5 | 0.040 |
Why?
| | Cytokine Receptor gp130 | 1 | 2018 | 10 | 0.040 |
Why?
| | North America | 1 | 2019 | 263 | 0.040 |
Why?
| | Diarrhea | 1 | 2019 | 173 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2019 | 220 | 0.040 |
Why?
| | Abdominal Pain | 1 | 2019 | 136 | 0.040 |
Why?
| | Hydrazines | 1 | 2018 | 28 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 506 | 0.040 |
Why?
| | Linkage Disequilibrium | 1 | 2019 | 268 | 0.040 |
Why?
| | Appendicitis | 1 | 2019 | 110 | 0.040 |
Why?
| | Quinoxalines | 1 | 2018 | 61 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 148 | 0.040 |
Why?
| | Osteosarcoma | 1 | 2018 | 66 | 0.040 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2018 | 156 | 0.040 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 107 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2019 | 194 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 280 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 273 | 0.040 |
Why?
| | Mice, Mutant Strains | 2 | 2008 | 271 | 0.040 |
Why?
| | Computer Simulation | 1 | 2021 | 882 | 0.040 |
Why?
| | Leukocytes | 1 | 2018 | 284 | 0.040 |
Why?
| | DNA Methylation | 1 | 2021 | 502 | 0.040 |
Why?
| | HLA Antigens | 1 | 2018 | 224 | 0.040 |
Why?
| | Up-Regulation | 1 | 2020 | 824 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 563 | 0.040 |
Why?
| | Molecular Structure | 1 | 2018 | 447 | 0.040 |
Why?
| | Ventricular Function, Left | 1 | 2020 | 469 | 0.040 |
Why?
| | Staining and Labeling | 1 | 2017 | 139 | 0.030 |
Why?
| | Recovery of Function | 1 | 2020 | 576 | 0.030 |
Why?
| | Medical Informatics | 1 | 2017 | 94 | 0.030 |
Why?
| | Embryo, Mammalian | 2 | 2007 | 215 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 742 | 0.030 |
Why?
| | Palliative Care | 1 | 2022 | 642 | 0.030 |
Why?
| | Tissue Array Analysis | 1 | 2015 | 49 | 0.030 |
Why?
| | Biomarkers | 2 | 2022 | 3474 | 0.030 |
Why?
| | Nephrectomy | 1 | 2017 | 150 | 0.030 |
Why?
| | Models, Statistical | 1 | 2019 | 612 | 0.030 |
Why?
| | Osteonectin | 1 | 2015 | 2 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2015 | 2404 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2019 | 1871 | 0.030 |
Why?
| | Caveolin 1 | 1 | 2015 | 21 | 0.030 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 275 | 0.030 |
Why?
| | Protein Conformation | 1 | 2018 | 822 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2017 | 526 | 0.030 |
Why?
| | Signal Transduction | 3 | 2019 | 4527 | 0.030 |
Why?
| | Sulfonamides | 1 | 2018 | 447 | 0.030 |
Why?
| | Genetic Variation | 1 | 2020 | 893 | 0.030 |
Why?
| | Immunoenzyme Techniques | 1 | 2015 | 193 | 0.030 |
Why?
| | Skin | 1 | 2019 | 668 | 0.030 |
Why?
| | Tissue Distribution | 1 | 2015 | 324 | 0.030 |
Why?
| | Cerebral Infarction | 1 | 2014 | 39 | 0.030 |
Why?
| | Mice, Nude | 1 | 2015 | 639 | 0.030 |
Why?
| | Thoracic Vertebrae | 1 | 2014 | 71 | 0.030 |
Why?
| | Dwarfism, Pituitary | 1 | 2013 | 3 | 0.030 |
Why?
| | Multiple Endocrine Neoplasia Type 2b | 1 | 2013 | 6 | 0.030 |
Why?
| | Fatal Outcome | 1 | 2014 | 286 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2015 | 850 | 0.030 |
Why?
| | Models, Molecular | 1 | 2018 | 1391 | 0.030 |
Why?
| | Disease Progression | 1 | 2020 | 2423 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 140 | 0.030 |
Why?
| | Hyperplasia | 1 | 2013 | 166 | 0.030 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1277 | 0.030 |
Why?
| | Microscopy, Electron | 1 | 2013 | 409 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2022 | 3587 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2015 | 1060 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2013 | 3914 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2014 | 217 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2023 | 2164 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2013 | 378 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2013 | 299 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 514 | 0.020 |
Why?
| | Amino Acid Sequence | 2 | 2006 | 2003 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2502 | 0.020 |
Why?
| | Cell Line | 2 | 2007 | 2657 | 0.020 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2015 | 638 | 0.020 |
Why?
| | Protein Binding | 2 | 2007 | 1918 | 0.020 |
Why?
| | Gene Expression Profiling | 2 | 2009 | 1550 | 0.020 |
Why?
| | Heart Arrest | 1 | 2014 | 289 | 0.020 |
Why?
| | Reactive Oxygen Species | 1 | 2013 | 550 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 4673 | 0.020 |
Why?
| | Leukemia Virus, Murine | 1 | 2009 | 16 | 0.020 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 92 | 0.020 |
Why?
| | Interferon Regulatory Factors | 1 | 2009 | 30 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2009 | 48 | 0.020 |
Why?
| | Transduction, Genetic | 1 | 2009 | 121 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2009 | 241 | 0.020 |
Why?
| | Granulocytes | 1 | 2008 | 78 | 0.020 |
Why?
| | Water Movements | 1 | 2008 | 22 | 0.020 |
Why?
| | Mice, Inbred C57BL | 2 | 2009 | 4779 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2009 | 445 | 0.020 |
Why?
| | Sewage | 1 | 2008 | 27 | 0.020 |
Why?
| | Leupeptins | 1 | 2007 | 10 | 0.020 |
Why?
| | Connectin | 1 | 2007 | 30 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2015 | 2581 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 562 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 278 | 0.020 |
Why?
| | Ubiquitin | 1 | 2007 | 65 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 136 | 0.020 |
Why?
| | Hematopoiesis | 1 | 2008 | 175 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2008 | 272 | 0.020 |
Why?
| | Mice, Inbred ICR | 1 | 2006 | 111 | 0.020 |
Why?
| | Isoenzymes | 1 | 2007 | 287 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2006 | 74 | 0.020 |
Why?
| | Protein Methyltransferases | 1 | 2006 | 2 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2009 | 388 | 0.020 |
Why?
| | Gene Deletion | 1 | 2007 | 356 | 0.020 |
Why?
| | Veins | 1 | 2006 | 57 | 0.020 |
Why?
| | Lung | 1 | 2018 | 3683 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2007 | 780 | 0.020 |
Why?
| | Monocytes | 1 | 2008 | 504 | 0.020 |
Why?
| | Cell Movement | 1 | 2009 | 867 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 605 | 0.020 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2006 | 96 | 0.020 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 226 | 0.020 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2008 | 289 | 0.010 |
Why?
| | Enhancer Elements, Genetic | 1 | 2005 | 153 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2007 | 924 | 0.010 |
Why?
| | Arteries | 1 | 2006 | 250 | 0.010 |
Why?
| | Protein Structure, Tertiary | 1 | 2006 | 804 | 0.010 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2006 | 389 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3072 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1442 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2005 | 1317 | 0.010 |
Why?
| | Pregnancy | 1 | 2008 | 5555 | 0.010 |
Why?
|
|
Arnold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|